Lopinavir and Ritonavir Tablets Assay Method Following United States Pharmacopeia Monograph Guidelines Using an Ascentis C8 Column and UV Detection

Introduction

This application note illustrates how it is possible to set-up an assay method for Lopinavir and Ritonavir tablets. The given experimental conditions follow the current USP43-NF38 monograph; the chromatographic assay method (HPLC-UV) is isocratic in nature and calls for an L7 column (octyl silane; C8 modification). The method has been validated following the guidelines in USP General Chapters <621>, <1225>, and <1226>.

Lopinavir and Ritonavir were baseline resolved (Rs > 5) within 40 minutes using an Ascentis C8 HPLC column (150 x 4.6 mm, 5 µm) with a mixture of 4.1 g/L monobasic potassium phosphate solution, acetonitrile, methanol, and tetrahydrofuran as the mobile phase. Under the applied conditions ritonavir elute prior to lopinavir, and all system suitability requirements are met. The method demonstrates good selectivity, reproducibility, sensitivity and accuracy.

Ritonavir

Figure 1.Ritonavir

Lopinavir

Figure 2.Lopinavir

Experimental Conditions

System Suitability Solution
System Suitability Solution

Chromatographic Data (System Suitability Solution)

Ritonavir Linearity

Lopinavir Linearity

Materials
Loading

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.